News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Positive Results for D-Pharm Ltd.'s Investigational Drugs in Models of Human African Trypanosomiasis and Malaria


8/20/2013 9:10:34 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REHOVOT, Israel, August 19, 2013 /PRNewswire/ --

D-Pharm Ltd., (TASE: DPRM) announced today on-line publication of promising results with its drug candidates, DP-460 and DP-b99, in models of human African trypanosomiasis (HAT) and malaria. These exciting results, demonstrate the potential of D-Pharm's proprietary platform technology, Membrane Active Chelators (MAC), to address these devastating parasitic diseases.

Malaria and HAT are a major world health problem with very few therapeutic options. Most of the available treatments are decades old and suffer from limited efficacy or undesirable side effects. For both malaria and HAT, new therapies targeting novel mechanisms and pathways are urgently needed.

Malaria is transmitted by mosquitoes and caused by intracellular protozoan parasites from the genus Plasmodium. The trypanosomes causing HAT (commonly known as sleeping sickness), are transmitted via the tse-tse fly. Plasmodium and Trypanosoma may have unique and essential requirements for divalent metal ions which prompted this investigation. The study, performed by a team led by Dr. Dennis Grab at The Johns Hopkins University School of Medicine's Department of Pathology, revealed that two MAC drugs, DP-b99 and DP-460, were effective against these parasites and drug potency was maintained for at least 24 h. The data were published for the first time on-line in Parasitology International journal (Volume 62, 5, 2013, 461-463). While the exact mechanism of action of MACs against intracellular malaria and extracellular African trypanosome parasites has yet to determined, their potential as anti-parasitic agents warrants further investigation.

About the technology

Disrupted metal ion homeostasis is symptomatic of numerous diseases, ranging from inflammation, cardiac arrhythmia, myocardial infarction and acute stroke to chronic neuro-degeneration (e.g. Alzheimer's and Parkinson's diseases). D-Pharm's breakthrough was to recognize metal ion distribution within cell membranes as a distinct, novel target for therapeutic intervention.

D-Pharm's platform technology enables rational design of lipophilic drugs to modulate the distribution of metal ions such as copper, zinc, calcium and iron selectively within cell membranes and membrane milieus, rendering their action localized and safe. D-Pharm has focused on developing MACs for age-related and degenerative diseases.

About D-Pharm

D-Pharm (http://www.dpharm.com) is a clinical stage, technology-driven biopharmaceutical company developing proprietary products for treatment of CNS disorders. D-Pharm's pipeline includes clinical stage II products, as well as a rich preclinical development pipeline for Alzheimer's disease, and other types of dementia.

Disclaimer

Statements in this press release that are not historical facts are forward-looking information, as defined in the Securities Law, based on information available to D-Pharm at the time of this press release. The estimations could, some or all, be unrealized, or could be realized in significantly different ways than expected.

For further information please contact:

Tami Horovitz

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES